OKYO Pharma Ltd (OKYO) CFO details equity and option positions
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
OKYO Pharma Ltd’s chief financial officer, Keeren Rameshchandra Shah, reports his existing equity stake in the company. He holds 16,667 shares of common stock directly. The filing also lists multiple option awards over common stock, including grants for 31,250 shares at a 1.50 exercise price expiring in 2035 and 25,193 shares at a 2.13 exercise price expiring in 2033.
Positive
- None.
Negative
- None.
Insider Trade Summary
27 transactions reported
Mixed
27 txns
Insider
Shah Keeren Rameshchandra
Role
CHIEF FINANCIAL OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | COMMON STOCK | -- | -- | -- |
Holdings After Transaction:
Options — 25,192 shares (Direct, null);
COMMON STOCK — 16,667 shares (Direct, null)
Footnotes (1)
Key Figures
Direct common shares: 16,667 shares
Option grant A: 31,250 underlying shares at 1.50
Option grant B: 21,667 underlying shares at 1.46
+2 more
5 metrics
Direct common shares
16,667 shares
Total common stock held directly by CFO after reported holdings
Option grant A
31,250 underlying shares at 1.50
Options over common stock expiring 2035-03-25
Option grant B
21,667 underlying shares at 1.46
Options over common stock expiring 2034-03-13
Option grant C
21,250 underlying shares at 1.57
Options over common stock expiring 2033-10-20
Option grant D
25,193 underlying shares at 2.13
Options over common stock expiring 2033-03-14
Key Terms
Options, exercise price, expiration date, underlying security shares
4 terms
Options financial
"security_title: "Options" with underlying common stock and exercise prices"
Options are contracts that give investors the right to buy or sell an asset at a specific price within a certain time frame. They function like a reservation or a ticket that allows for potential profit or protection against price changes, making them useful tools for managing investment risks or speculating on market movements.
exercise price financial
"conversion_or_exercise_price fields such as "1.5000" and "2.1300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date fields such as "2035-03-25T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What stock options in OKYO Pharma (OKYO) does the CFO report?
The CFO reports several option grants over OKYO Pharma common stock, including tranches for 31,250 underlying shares at a 1.50 exercise price expiring in 2035. Additional grants cover tens of thousands of shares with exercise prices between 1.46 and 2.13 and expirations through 2035.
What are examples of strike prices and expirations for OKYO Pharma (OKYO) CFO options?
Reported options include underlying shares at a 1.50 exercise price expiring on 2035-03-25 and at a 2.13 exercise price expiring on 2033-03-14. Other awards use exercise prices of 1.46 and 1.57, generally expiring between 2033 and 2035.